BioNxt Advances Cladribine ODF for Multiple Sclerosis and Myasthenia Gravis

BioNxt Solutions Inc. reported significant progress in its cladribine oral thin film (ODF) program, achieving over 40% improvement in bioavailability. This milestone supports the transition to human clinical studies for Multiple Sclerosis (MS). The program benefits from the established profile of cladribine, focusing on bioavailability rather than large-scale safety trials. BioNxt collaborates with a clinical research organization to ensure regulatory compliance and efficient execution.

The Myasthenia Gravis (MG) program builds on the same technology, utilizing cladribine to address swallowing challenges. The MG market is projected to reach USD 6.7 billion by 2032. BioNxt's sublingual thin film aims to enhance patient adherence across neurological conditions. Their strategic approach combines advanced drug delivery systems with capital efficiency.